Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis
Makaleler > Tam Makale · 2017
Yazarlar: Cumali Efe, Hannes Hagstrom, Henriette Ytting, Rahima A. Bhanji, Niklas F. Muller, Qixia Wang, TUĞRUL PÜRNAK, Luigi Muratori, Marten Werner, Hanns-Ulrich Marschall, Paolo Muratori, Fulya GÜNŞAR, Daniel Klintman, Albert Pares, Alexandra Heurgue-Berlot, Thomas D. Schiano, Mustafa Cengiz, Michele May-Sien Tana, Xiong Ma, Aldo J. Montano-Loza, Thomas Berg, Sumita Verma, Fin Stolze Larsen, Ersan Ozaslan, Michael A. Heneghan, Eric M. Yoshida, Staffan Wahlin
Clinical Gastroenterology and Hepatology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2017, cilt 15, ss 1950-1956.e1
DOI: 10.1016/j.cgh.2017.06.001
Özet
BACKGROUND & AIMS: Predniso(lo) ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.